[Chosun Biz] [Law Firm's Technology] The First Case to Admit a Domestic Pharmaceutical Company’s Patent Infringement Claim under the Doctrine of Equivalents... Lee & Ko’s Landmark Success in Protecting Boryung’s Original Hypertension Drug

On May 4, 2022, Lee & Ko Healthcare Team’s successful winning of the case for defending Boryung Pharmaceutical’s patent relating to Ducarb®, a domestic blockbuster drug, against a generic company’s challenge was introduced by Chosun Biz as well as Korea Economic Daily.

Chosun Biz said, “As this trial decision is not only the primary case where a Korean pharmaceutical company held off a large-scale generic drug company’s challenge against an original drug but also the first case in which such Korean pharm company’s patent infringement claim under DOE was admitted, the industry now closely pays attention to this case in that the IPTAB(Intellectual Property Trial and Appeal Board) may also follow the standard of this trial decision in the remaining trials for 40 other companies.”